CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 899.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.50M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.50M.
Fairly Valued
The company’s latest PE is -1.89, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.58M shares, increasing 25.65% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 18.15K shares of this stock.